Loading...
•
Mar 31, 2024
Carisma Therapeutics Q1 2024 Earnings Report
Carisma Therapeutics reported financial results for Q1 2024 and highlighted recent business updates.
Key Takeaways
Carisma Therapeutics reported their Q1 2024 financial results, focusing on the development of CT-0525 and CT-0508, and presented preclinical data in liver fibrosis. The company's cash and cash equivalents are expected to fund operations into the third quarter of 2025.
Announced CT-0525 as the lead product candidate for the anti-HER2 program, with initial data expected by year-end 2024.
Presented preclinical proof of concept data in liver fibrosis at ASGCT, expecting to nominate a development candidate in Q1 2025.
Presented Regimen Level 1 data from Phase 1 sub-study utilizing CT-0508 in combination with pembrolizumab at AACR; Regimen Level 2 data expected in Q2 2024.
Cash and cash equivalents of $56.5 million are expected to fund the company into the third quarter of 2025.
Revenue by Segment
Forward Guidance
Carisma anticipates that its cash and cash equivalents of $56.5 million as of March 31, 2024, combined with the expected cost savings from implementing the revised operating plan, are sufficient to sustain its planned operations into the third quarter of 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...